Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,…

Apoptosis assays marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.10% in the forecast period of 2020 to 2027 and is expected to reach USD 8.80 billion by 2027.

Apoptosis Assays market research report utilizes the graphs and charts which turns it into more visually appealing. This makes available the best way to the users to understand customer and thus increase their satisfaction by answering the needs and expectations. It also helps to see what factors are influencing the business, where the brand is situated, and get the temperature of the market before a product is launched. Once all the market analysis and studies are done, it is time to present them efficiently, so as to onboard everyone and make the right decisions for the business strategy market research reports are the key partners in the matter.

Download Sample PDF Copy of Report + All Related Graphs @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-apoptosis-assays-market

The major players covered in the apoptosis assays market report areMerck Group, Thermo Fisher Scientific, Inc., BD, Bio-Rad Laboratories, Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG, Biotium, Inc., Creative Bioarray, GE Healthcare, Danaher Corporation, Geno Technology Inc, GeneCopoeia, Inc, Bio-Techne, PerkinElmer, Promega, General Electric and BioTek among other domestic and global players.

Segmentation:Global Apoptosis Assays Market

Apoptosis Assays MarketBy Product

(Assay Kits, Reagents, Microplates, Instruments),

Apoptosis Assays Market By Technology

(Flow Cytometry, Cell Imaging & Analysis Systems, Spectrophotometry, Other Detection Technologies),

Apoptosis Assays Market By End User

(Pharmaceutical and Biotechnology Companies, Hospital and Diagnostic Laboratories, Academic and Research Institutes),

Apoptosis Assays Market By Application

(Drug Discovery & Development, Clinical & Diagnostic Applications, Basic Research, Stem Cell Research),

Apoptosis Assays MarketBy Country

(U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa)

Enquire Here Get customization & check discount for report @:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-apoptosis-assays-market

Global Apoptosis Assays Market Drivers & Restraints:

The increasing cell-based research will help in escalating the growth of the apoptosis assays market.

The increasing incidence and prevalence of chronic and infectious diseases, development of apoptosis-modulating drugs, rising funding for cancer research, growing population suffering from chronic and autoimmune diseases are some of the factors expected to drive the growth of the apoptosis assays market in the forecast period of 2020 to 2027.

On the other hand, the growing adoption of apoptosis assays in developing markets will create several opportunities that will lead to the growth of the apoptosis assays market in the above mentioned period.

Lack of skilled personnel for research and development of apoptosis assays will likely to hamper growth of the apoptosis assays market in the above mentioned period.

Table of Contents:

Know More About Apoptosis assays market @https://www.databridgemarketresearch.com/reports/global-apoptosis-assays-market

Key points for analysis

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email:Corporatesales@databridgemarketresearch.com

Follow this link:
Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,...

Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer…

Written by AZoMFeb 16 2021

Dublin, Ireland, 16 February 2021 Tibidabo Scientific Industries Ltd (Tibidabo Scientific), a global leader and supplier of highly differentiated technology for scientific research, aerospace, and industrial markets, has today announced the appointment of John LaViola as its Chief Technology Officer (CTO) and Head of Business Development.

John LaViola

We are honored to welcome John to our team. As a visionary executive, his technology leadership, scientific rigor, and unique insights are well-known throughout the scientific imaging community. Johns appointment comes at an exciting time for our company, as we accelerate technological innovation and expansion of our growing product offering, explained Paul Murtagh, Chairman & Chief Executive Officer at Tibidabo Scientific. In organizations ranging in size and complexity from early stage to global enterprises, John has been managing R&D and Business Development of medical device, scientific, and imaging systems for over 35 years across a broad range of clinical and scientific disciplines. We are looking forward to harnessing his unique skillset across our expanding business.

Mr. LaViola will lead the companys technology vision and strategy, define the future direction of R&D, and oversee our Mergers & Acquisitions execution and integration. Since 2014, John has served as Vice President, Business Development, and in 2018 assumed leadership for Strategic Innovation in Hologic, Inc.s (Nasdaq: HOLX) Breast and Skeletal Health Solutions division. At Hologic, John was responsible for mergers and acquisitions, technology partnerships, and business alliances, as well as product and service innovation strategy in Hologics largest business unit. He led numerous public and private acquisitions, as well as consummated several strategic partnerships. With a lengthy track record of developing and commercializing disruptive innovations, John previously held technology leadership roles as Vice President, R&D from 2008, and as Senior Director, R&D from 2002 at Hologic.

To learn more, please visit http://www.tibidaboscientific.com

Tibidabo Scientific Industries is a global leader and supplier of highly differentiated technology for scientific research, aerospace, and industrial markets. We succeed by helping customers push boundaries in radiobiology, stem cell research, high-performance imaging, radiation detection, surveillance, space exploration and advanced scintillators. With our roots dating back to H2S phosphor screens in radar critical to the Allied defense during World War II, the impact of our products is now felt from the deepest recesses of the earth, to cutting-edge cancer research, and to the far reaches of space. Our collaborative approach and expanding global team enable our customers to make smarter decisions and adopt more effective solutions with ground-breaking technologies. Our philosophy, culture and strategy are guided by the Tibidabo Business Matrix (TBM), a customer, quality, performance and people-oriented management approach with a system of continuous improvement at its core. For further information, please contact Diane Brau, Corporate Communications [emailprotected]

More:
Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer...

How Irish medtech came to thrive – Med-Tech Innovation

Dr Paul Anglim, partnership development lead for EIT Health Ireland-UK, takes a look at how Irelands thriving medtech ecosystem came to be, and why it continues to go from strength to strength.

In understanding Irelands success in medtech, its important to look at how Ireland turned around its manufacturing slump to become a hotspot for nine of the worlds top ten medtech companies.

The origins of its prosperous medtech sector can be traced back to its highly-skilled manufacturing workforce and strategic government support. When the manufacturing industry suffered a downturn in the 1980s, both the Irish government and those running the sites wanted to safeguard and grow the field of manufacturing.

For them, it was time to embed R&D and innovation into medtech.

Making Ireland an attractive place for R&D

Over the next few decades, the Irish governments strategy went beyond offering physical space and taxation grants, with the development of strategic funding agencies and initiatives.

In 2015, the Science Foundation Irelands CRAM Centre for Research in Medical Devices launched Irelands first stem cell manufacturing centre at NUI Galway. With the goal of positioning Ireland as the leader in medical device technology development, the SFI CRAM focusses on delivering affordable transformative solutions for chronic diseases.

Other collaborations between the government, health services and leading universities have further cemented R&D in industry and Irelands healthcare system. Take, for example, the establishment of the Health Innovation Hub Ireland (HIHI) at University College Cork in 2016.

Backed by Enterprise Ireland and the Health Service Executive, the HIHI incorporatespartnering institutes Trinity College Dublin, NUI Galway, Cork Institute of Technology (CIT) andassociated hospital groups to lead on ground-breaking research and harness new healthcare technology, services and products.

The development of clinical and patient-focussed research has paved the way for Ireland to lead on the exchange of technology ideas. According to IDA Ireland,government grant assistance is responsible for 70% of medtech companies in Ireland engaging in research and development activities.

The goal to entrench R&D in the medtech sector is fast becoming a reality.

Industry and government alignment

As the medtech industry looks drive its growth, alignment between governmental agencies and key associations have played a major role in making this possible.

The IDA has made Ireland an attractive place to do business. The break-up of the IDA into three separate organisations in the mid-1990s enabled it to focus on driving high-quality foreign direct investment in Ireland. The US-based medtech company Strykers 2019 investment of more than 200 million in R&D at its Cork facilities is just one example of the IDAs success in brokering landmark deals.

Underscoring its support of industry, the IDA recently announced that it is set to deliver a targeted COVID-19 fund, investing a total of 200 million in medical technologies and pharmaceuticals.

In addition to the IDA, the Irish Medtech Association has been vital in championing the needs of multinationals corporations and SME member companies to the Irish government. Sitting within Ibec, the Irish Medtech Association has a clear grasp on what the actual needs of industry are, how to represent them to governmental bodies and how to ensure Ireland remains a key location for companies to base their operations.

A burgeoning entrepreneurial mindset

There has also been shift in perception on what is means to be an entrepreneur. People want people to be successful. The entrepreneurial mindset is common among university students of today and theres an abundance of university-led programmes to develop innovative ideas.

NUI Galways BioInnovate Fellowship programme has paved the way for a plethora of successful medtech start-ups. Supported by Enterprise Ireland, BioInnovate delivers needs led innovation based on a proven Stanford BioDesign framework, identifying where recommended solutions would have the most impact.

BioInnovate, like other university-led fellowships, is physically housed in the same place as earlier stage programmes, enabling innovators to meet, network and share new ideas.

In these spaces, the entrepreneurial mindset is the norm, and new innovators emerge in Irelands medtech sector.

Ireland as a thriving medtech ecosystem

Taking into account the support from government agencies, industry, clinical and academic institutions, the existence of Irelands 300-plus community of medtech companies can be better understood.

It is in this dynamic environment that EU-backed organisations like EIT Health, a network of leading health innovators, have decided to expand their presence in Ireland.

Read more:
How Irish medtech came to thrive - Med-Tech Innovation

Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,…

According to the new market research report of Index Markets Research, theCell Expansion Market by Product Type(Human cells, Animal cells),by Application (Regenerative Medicine and Stem Cell Research, Cancer and Cell-based Research, Others) and by Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) Global Forecast to 2026. The worldwide Cell Expansion Market size in 2021 is assessed at USD XX.XX billion and is projected to arrive at USD XX.XX billion by 2026, at a CAGR of X.X% from 2021 to 2026.[Get a Free Sample PDF Report to Understand our Report Before You Purchase]The report helps in evaluating the current situation of the worldwide Cell Expansion market scene and henceforth supporting the customers in settling on educated choices identified with their business systems and speculations. The report likewise subtleties a solid appraisal of the effect of the COVID-19 pandemic on the Cell Expansion market and has a record of systems and strategies embraced by significant parts in the Cell Expansion market to guarantee most extreme profitability and productivity.

What does the Report Include?

The market report incorporatessubjective and quantitative analysisof a few factors, for example, thekey driversand restrictions that will affect development. Furthermore, the report gives bits of knowledge into theterritorial analysisthat covers various areas, adding to the development of the market. It incorporates thecompetitive landscapethat includes the main organizations and the reception of procedures to declare associations, present new products, and team up to additionally add to the development of the market somewhere in the range of 2021 and 2026. In addition, the analysis investigator has embraced a few explorationstrategies to separate data about the latest thingsand industry improvements that will drive the market development during the forecast period.

Key benefits for stakeholders

Porters five powers investigation helps the capability of the purchasers and providers and the serious situation of the industry for strategy building. It diagrams the latest things and future estimations of the market from 2021 to 2026 to comprehend the predominant chances and potential venture pockets. The significant nations in the area have been planned by their individual income commitment to the regional market. The key drivers, restrictions, and opportunities and their definite effect analysis are clarified in the investigation. The profiles of vital participants alongside their key vital advancements are enrolled in the report.

Browse Detailed Research report @https://www.indexmarketsresearch.com/report/global-cell-expansion-market-8/471256/

What Are The Market Factors That Are Explained In The Report?

Key Strategic Developments:The investigation additionally incorporates the key advancements of the market, involving R&D, new product dispatch, M&A, arrangements, coordinated efforts, organizations, joint endeavors, and provincial development of the main rivals working in the market on a worldwide and local scale.

Analytical Tools:The Cell Expansion Market Report incorporates the precisely contemplated and surveyed information of the key business players and their extension in the market by methods for various insightful instruments. The logical devices, for example, Porters five powers investigation, SWOT examination, plausibility study, and speculation return examination have been utilized to dissect the development of the central participants working on the lookout.

Key Market Features:The report assessed key market highlights, including income, value, limit, limit usage rate, net, creation, creation rate, utilization, import/trade, supply/request, cost, piece of the pie, CAGR, and gross edge. Also, the investigation offers an extensive investigation of the key market elements and their most recent patterns, alongside appropriate market portions and sub-fragments.

Detailed Table of Content:

1. Introduction Research Scope Market Segmentation Research Methodology Definitions and Assumptions 2. Executive Summary 3. Market Dynamics Market Drivers Market Restraints Market Opportunities 4. Key Insights Key Emerging Trends: For Major Countries Key Developments: Capacity Expansions, Acquisitions, Partnerships, etc. Latest Technological Advancement Insights on Regulatory Scenario Porters Five Forces Analysis 5. Qualitative Insights on Impact of COVID-19 on Global Cell Expansion Market Supply Chain Analysis & Challenges due to Covid-19 Steps taken by Government / Companies to Overcome this Impact Potential Challenges and Opportunities due to COVID-19 Outbreak 6. Global Cell Expansion Market Analysis, Insights and Forecast, 2016-2027 Key Findings / Summary Market Size Estimates and Forecast -By Product (Value and Volume) -By Application (Value and Volume) -By Region (Value and Volume) North America Europe Asia Pacific Latin America Middle East & Africa

TOC Continued!https://www.indexmarketsresearch.com/report/global-cell-expansion-market-8/471256/#toc

Why us?

We encourage you with a urgent detailed knowledge report on the Cell Expansion market. We structure the reports to build your work process effectiveness. Descriptive graphs, logical outlines, and more scientific instruments to give the customers more authentic information in successful yet easy to grasp illustrations. We give you a report that teaches you on the difficulties and issues of the Cell Expansion market and gives you information expected to beat those issues and expand your development potential.

Contact Us On: Phone:+1-202-888-3519 Email:sales@indexmarketsresearch.com Web:www.indexmarketsresearch.com

Link:
Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,...

The PRP Alternative to Knee and Other Surgeries – Sahuarita Sun

Last month we talked about using hyaluronic acid (HA) injections as an alternative to knee replacement surgery. Another alternative to knee replacement is platelet rich plasma, known simply as PRP.

PRP promotes natural healing.

Steroid injections have been one of the standard treatments used as an alternative to knee surgery. But steroids have limitations in how often they can be used, and may not work well for long-term results.

PRP uses the patients own blood components. After blood is drawn, it is placed into a centrifuge, which spins to isolate the platelets. The PRP is then injected into the affected area. The concentrated PRP promotes healing of the injured or inflamed area. Relief begins within a few weeks of the injection, and pain decreases even more as the healing continues.

In addition to being a viable alternative to knee surgery, PRP is effective for rotator cuff issues, pelvic pain and instability, tennis elbow, tendonitis, muscle strains and more.

Now at affordable prices.

Insurance may or may not cover PRP, but it is now affordable enough for most patients to pay for PRP on their own.

For more information, call Pima Orthopedics at 520-624-0888 and ask about the Non-Surgical Knee Relief Program at our Tucson and Green Valley offices.

See the original post:
The PRP Alternative to Knee and Other Surgeries - Sahuarita Sun

Platelet Rich Plasma Market: Applications, Business Trends by Size 2021: Growth Statistics and Key Players Insights by Types, and Development Analysis…

The rising prevalence of the arthritis is augmenting the demand of the blood products, which is ultimately helping the growth of the platelet-rich plasma market.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999558

Key Market Trends:

Pure PRP Segment by Type is Expected to Hold the Largest Market Share

The pure PRP segment of the global platelet rich plasma market is believed to have the largest market share.

The prime factor responsible for the growth of this segment is the significance of this type of platelet plasma for the person. Pure PRP has an edge over traditional PRP, as it requires a two-step concentration process that helps in eliminating unwanted red blood cells (RBCs) and neutrophils. RBCs (that have no therapeutic effects for regeneration) can create a more viscous solution that can be more painful when injected. Neutrophils, a type of white blood cell, have inflammatory components that may increase pain and inflammation post-treatment.

Pure PRP helps the stem cells and regenerative cells in the repair and in rebuilding the damaged tissue. This ultimately speeds up the healing process and reduces pain. In addition, it promotes increased strength and improves the overall function. Therefore, owing to the contribution of pure PRP in the healing process and the rising use of it as a blood product, the segment is expected to dominate the market in the coming future.

North America Dominates the Market and is Expected to Continue the Same Trend for Next Few Years

North America currently dominates the platelet-rich plasma market and is expected to continue its stronghold for a few more years. The United States is a major market, and this is mainly due to the US governments initiatives to develop blood products. In addition, the emergence and adoption of novel technologies are going to help the market in a positive manner.

Reasons to Purchase this Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999558

Key questions answered in the report:

Detailed TOC of Platelet Rich Plasma Market Segmented by Geography Growth, Trend, and Forecast:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Incidences of Sports Injuries 4.2.2 Increasing Number of Androgenic Alopecia Patients 4.2.3 Growing Use of Platelet-rich Plasma in Various Therapeutic Areas 4.2.4 Rising Prevalence of Arthritis 4.3 Market Restraints 4.3.1 Stringent Regulatory Policies 4.3.2 High Prices of Plasma Therapy 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Type 5.1.1 Pure PRP 5.1.2 Leukocyte-rich PRP 5.1.3 Pure Platelet-rich Fibrin 5.1.4 Leukocyte-rich Fibrin 5.2 By Source 5.2.1 Autologous 5.2.2 Allogenic 5.3 By Application 5.3.1 Orthopedic 5.3.1.1 Arthritis 5.3.1.2 Chronic Tendinitis 5.3.1.3 Bone Repair and Regeneration 5.3.2 Dermatology 5.3.2.1 Androgenic Alopecia 5.3.2.2 Plastic Surgery 5.3.2.3 Cardiac Muscle Injury 5.3.2.4 Dental 5.3.2.5 Nerve Injury 5.3.2.6 Other Applications 5.3.3 By End User 5.3.3.1 Hospitals and Clinics 5.3.3.2 Research Institutes 5.3.3.3 Other End Users 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 Australia 5.4.3.5 South Korea 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East & Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East & Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Bio Product Laboratory Ltd (BPL) 6.1.2 Biolife Plasma Services 6.1.3 Biotest AG 6.1.4 Cambryn Biologics LLC 6.1.5 China Biologic Products Inc. 6.1.6 CSL Ltd 6.1.7 Grifols International SA 6.1.8 Kedrion SpA 6.1.9 LFB SA 6.1.10 Octapharma AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Folding Box Board Market Size and Share Analysis 2020: with Covid-19 Impact on Global Business Growth, Forthcoming Developments Forecast to 2026 | Industry Research.co

Ultra-High Strength Steel Market Growth Rate and Business Share 2020: Global Industry Current Trends, Top Companies, Sales and Drivers Analysis Research Report to 2026 | Industry Research.co

Paper Processing Resins Market Share Value Analysis with Key Technologies 2021 Market Dynamics of Key Players, Global Opportunities, Demand Status Forecast till 2026

Lactose-free Milk Powders Market Size Report 2021: Covid-19 Impact Analysis with Top Key Players, Global Industry Share, Future Scope, Business Strategies and Demand Forecast to 2026

Data Center Power Market Share and Forecast Analysis 2021-2023 | Latest Developments of Industry, Segmentation, Global Growth Trends and Business Strategies with Covid-19 Impact

Brushless DC Motors Market Size Trends and Vendor Analysis 2021: includes Drivers and Challenges, Value Chain Analysis by Global Share, Scope and Growth Technology Forecast to 2024 Industry Research.co

Swimming Equipment Market- 2020 Growth and Business Prospects, Industry Size Forecast by Share, Revenue, Development Status, Demand by Regions, Market Potentials Analysis till 2026

Laminated Reel Labels Market Share and Size Analysis 2020 Global Industry Segments by Regions, Types and Applications, Future Demand Status, Growth Dynamics with COVID-19 Impact till 2026

Car Leasing Market Growth Analysis 2020 Recent Trends by Regions, Future Demand Status, Size and Share Value Analysis, Boosting Strategies, COVID-19 Impact by 2024

Vaccine Adjuvants Market 2020 by Top Countries Data with Share Analysis, Global Growth Trends, Market Size by Top Players, Geographical Segmentation Forecast to 2024

3D Computer Graphics Software Market Size Analysis 2020 with Business Boosting Technologies, Forthcoming Growth Rate, Top Regions, Key Players and Investments Opportunities Forecast to 2025

High Performance Plastics Market Size and Share Analysis 2020 Global Future Growth Rate, Industry Players, Developments Status, Trends Forecast to 2026 | Industry Research.co

https://neighborwebsj.com/

Link:
Platelet Rich Plasma Market: Applications, Business Trends by Size 2021: Growth Statistics and Key Players Insights by Types, and Development Analysis...

Coping With Cancer Treatment’s Effects on Skin – Curetoday.com

As she walked into Memorial Sloan Kettering Cancer Center, Erin Hazelton was struck by the appearance of the woman in front of her. Hazelton was at the New York, New York, cancer center to begin treatment for stage 2 invasive ductal carcinoma.

I walked into the center right after another woman, and when I heard her give her date of birth (to the receptionist), I realized that she was only a couple of years older than me, but she looked like she was my mothers age, recalled Hazelton, who received her diagnosis in 2018. When you (get a diagnosis) at age 37 (like I did), its scary. So much of my identity was tied up in how I looked. I was terrified.

Although many cancers are unseen, different types of treatment can lead to painful, visible side effects. After starting treatment, Hazelton experienced skin side effects including universal hair loss; facial wrinkles and loss of collagen; melasma (dark/discolored patches) on her face; dry skin; seeping wounds; scars; and radiation tattoos.

In addition to the regular side effects of chemotherapy, which can be devastating to quality of life, newer targeted therapies and immunotherapies have additional side effects of the skin that can be very frequent and very specific, says Dr. Nicole LeBoeuf, a dermatologist at Brigham and Womens Hospital and director of the skin toxicities program at Dana- Farber Cancer Institute in Boston, Massachusetts.

According to LeBoeuf, systemic cancer treatments can generally be grouped into three categories, and the types of side effects patients could experience will depend on the patients treatment regimen and cancer type.

The first category is cytotoxic, or classic, chemotherapy, which most commonly causes side effects including alopecia, or hair loss; painful rashes on the hands and feet; and general rashes elsewhere on the body that can lead to swelling, pain and itchiness.

Hazeltons initial regimen included Adriamycin (doxorubicin), a chemotherapy drug known as the red devil because of its harsh side effects, followed up with Taxol (paclitaxel). I lost all my hair eyelashes, eyebrows, everything and my skin looked like I had aged a good 15 to 20 years toward the end of it, Hazelton says. My cheeks had wrinkles because the collagen wasnt being renewed; I had melasma, which I hadnt expected, that was made worse by the sun.

She also experienced skin-related side effects from radiation and scars from her lumpectomy. My skin started slowly breaking down over the course of my radiation, and at the end of six weeks, I had seeping wounds, Hazelton says. My nipple looked like it was going to separate from my body.

The second category of treatment that can lead to skin side effects are targeted therapies, which are linked to the specific drug used for that patients treatment. The most commonly talked-about skin side effect of targeted therapy is called a papulopustular, or an acne-like, rash from EGFR inhibitors, or drugs that target the epidermal growth factor receptor mutation. This mutation is found in lung cancers, head and neck cancers, some colon cancers and, rarely, in breast cancer, LeBoeuf says. In fact, 85% of patients who are treated with drugs that target that particular genetic mutation will develop that rash.

Another common skin side effect from targeted therapies is hand-foot skin reaction, which causes painful calluses and blisters on pressure points. These blisters can occur from doing very normal activities, LeBoeuf says. Something as simple as going to the grocery store can make a patients feet look like theyve just run a marathon. Someone who works on a keyboard may experience painful blisters on their fingertips when they type.

Severe skin side effects such as these can prevent patients from resuming everyday activities and make them more likely to discontinue their cancer treatment, leading to a worse prognosis.

The third category of treatment leading to skin side effects is immunotherapy, a type of treatment that boosts the bodys natural defenses, or immune system, to fight the cancer. Immunotherapy is a beast because once you unleash the immune system, you can turn on any and all skin diseases that would happen outside the cancer setting. Anything that could possibly happen in the field of dermatology has been triggered by activating the immune system, LeBoeuf says. It is amazing and it is groundbreaking...but it can also lead to autoimmune disease in any organ.

The most common skin-related side effects of immunotherapies include psoriasis, with bumpy red patches covered in white scales; vitiligo, or whitish patches from lost pigment; and lichen planus, an autoimmune disease that can cause swelling and irritation of the skin, hair, nails and mucous membranes.

Sometimes the adverse immune events that are activated through immunotherapy persist after the treatment has ended. Our approach to these side effects is always to try to uncouple the toxicity from the effects of the drug on the cancer, then target the side effects as specifically as possible, LeBoeuf says. This leaves the rest of the immune system intact to fight the cancer.

Given the variety of possible side effects and the degree to which it may affect a given individual, it can be hard for patients to know which ones to expect and how to manage them if they arise during and after treatment.

Dr. Anisha Patel, an associate professor of dermatology at The University of Texas MD Anderson Cancer Center in Houston, recommends that patients follow good hair, skin and nail habits before starting treatment: Moisturize often, avoid perfumed products, and decrease the use of lacquer on your nails, she says.

Patients who have a history of skin conditions prior to their cancer diagnosis are more likely to see worsening during treatment. If you already have eczema, psoriasis, or acne, those things are more likely to be exaggerated, Patel says. If you have a preexisting skin condition, that should be taken care of before your therapy starts, as well.

During treatment, certain practices can help prevent the most common side effects. For example, wearing ice- cold gloves and socks and using scalp cooling treatments to restrict blood vessels reduces the chances of hair loss and hand-foot syndrome.

Patients should also take steps at home to minimize side effects. Wearing sunscreen, avoiding direct sun exposure and wearing a hat when outdoors can prevent photosensitivity side effects, Patel says.

To manage her symptoms, Hazelton applied organic shea butter daily and wore gloves and socks to bed to keep her skin as moisturized as possible. My nails were actually amazing during treatment because I was moisturizing them so religiously, she says. Whatever your skin can drink up during that time that is nontoxic, contains no preservatives and has no scents will help.

For patients who are undergoing targeted therapy or immunotherapy, dealing with side effects can be more complicated. In general, the newer cancer therapies (like immunotherapy) have very specific side effects, which may require specific treatment, Patel says. Patients have to go into it with the mindset that they will have some sort of side effect and ask their treatment team what to expect and what they can do to minimize it.

LeBoeuf recommends that patients seek the advice of a dermatologist, who can work with the medical oncologist to manage skin side effects. Whenever possible, if a specific dermatologic diagnosis can (be) made, then the most appropriate treatment can be instituted as quickly as possible, LeBoeuf says. If you treat the side effect specifically, based on dermatologic literature, then often, patients will recover and can continue their cancer treatment, as well.

Both Patel and LeBoeuf urge that the mental and emotional side effects of treatment-related skin conditions receive as much attention as the physical side effects. Often, patients are embarrassed or they feel like they shouldnt be concerned about a side effect that isnt life-threatening, LeBoeuf says. But the reality is, if a side effect affects your quality of life, increases your stress or changes your course of treatment, it can also affect your ability to fight the cancer. So be open, ask for help and advocate for referrals if you feel you arent getting the treatment you need. Maintaining skin health can also prevent secondary problems such as infections or ulcers and can minimize scarring.

Taking one day at a time helped Hazelton maintain a positive mindset. Thinking Am I going to burn during radiation? or Whats my scar going to look like? doesnt help you mentally. Just approach it as it comes, she says.

Patients might be surprised to learn that there is a silver lining to skin-related side effects: Skin side effects to some of the newer targeted and immune therapies is correlated to having a better tumor response, Patel says. It is correlated to the bodys immune system being revved up to fight the cancer.

Post treatment, patients should be advised about options to help restore the health of their skin, hair and nails. What happens after the treatment isnt talked about as much, Dr. Anthony Rossi, a dermatologist and surgeon specializing in skin cancer, lasers and cosmetic surgery at Memorial Sloan Kettering Cancer Center, says. Radiation can cause chronic changes in the skin; surgery, obviously, leaves a lot of scars, and high-dose steroids can leave stretch marks that last forever.

To combat these side effects, Rossi and his team at Memorial Sloan Kettering are working on what they call restorative oncodermatology, which, he says, aims to restore patients who go through cancer treatment and help them get back the form and function of their skin.

Through the use of treatments such as topical retinoids, topical skincare, chemical peels, lasers, botulinum neurotoxin (such as Botox) and platelet- rich plasma (or PRP) injections an experimental therapy that uses injections of the patients own blood platelets to prompt hair growth Rossi reports that many survivors are seeing life-changing results. There is definitely a cosmetic aspect that people want to improve... but these treatments help with skin functionality and overall quality of life, most importantly, he says.

Hazelton has received chemical peels and laser treatments to reduce her wrinkles and melasma, as well as used over- the-counter eyelash serums to help her hair grow back.

I thought my life was over when I got my diagnosis. I thought I would never look the same or feel the same ... but there are people out there to help you fix these physical things that remind you of your sickness, she says. A lot of people bounce back more than they expect they will. ... Your body really does recover; you just have to give it a chance.

See the original post here:
Coping With Cancer Treatment's Effects on Skin - Curetoday.com

AI project to power the future of stem cell manufacturing – TechCentral.ie

Stem cell images from DeepStain project

Valitacell, CeADAR receive 242,000 from Enterprise Ireland and EU

Print

Read More: AI artifical intelligence CeADAR stem cells Valitacell

A new project to improve stem cell manufacturing using artificial intelligence (AI) could have lasting impacts for the health sector.

The three-year project, entitled DeepStain: Deep Learning for Cell Image Analysis hopes toaccelerate an area of drug development which is at the root of many diseases.

DeepStain is part of a strategic partnership between Irish biotechnology company Valitacell and CeADAR, Irelands Centre for Applied Artificial Intelligence.

The project has received 242,000 funding from Enterprise Ireland and the EU under the Marie Skodowska-Curie Co-Fund Scheme, which is part of the Horizon 2020 Research and Innovation programme.

Stem cells have the potential to treat many conditions including cancer, arthritis, and Crohns disease. Monitoring stem cell quality involves a lot of slow and difficult laboratory work, meaning they can behard to manufacture.

The DeepStain project will use AIto quickly analyse images of stem cells to determine their quality and make stem cell manufacturing more efficient.

The core team is composed of Dr Ricardo Simon Carbajo (CeADAR), Dr Paul Dobson (Valitacell) and Dr PolatGkta(CeADAR & Valitacell), and builds on previous work and interdisciplinary expertise.

AI can massively help to improve the Biopharma value chain, said Dr Ricardo Simon Carbajo, head of innovation & development at CeADAR. In this project, we will be applying the latest techniques in Computer Vision to speed up the process of manufacturing stem cells. We are delighted to partner with Valitacell as they are truly innovating in this area and we can produce a real impact in society.

Working with CeADAR will help Valitacell leverage the power of Deep Learning to create better bioprocess analytical technologies to support stem cell therapy manufacturing, said Dr Paul Dobson, head of data at Valitacell. This will help translate stem cells from being a niche experimental therapy into a treatment available to patients worldwide.

TechCentral Reporters

Read More: AI artifical intelligence CeADAR stem cells Valitacell

View All Events

This course is designed to give you and your team all of the tools you need to lift architecture from a documentation process to a true business capability. All IT architects will benefit from the concepts presented in this course. 16 February, 63 CPD Points, Online

The Certified Data Protection Officer Programme has been designed to equip Data Protection Officers with the necessary skills and competencies to meet and maintain all aspects of data protection compliance. 2 March, 63 CPD Points, Online

Be confident that your organisations policies and procedures are legally compliant with data protection legislation by completing Irelands first certified data protection practitioner programme. 9 March, 31.5 CPD Points, Online

Published by Mediateam Ltd., Ireland technology media leader since 1976, 55 Spruce Ave, Sandyford, Dublin 18, A94 N125.

Privacy & Cookies Policy

Continued here:
AI project to power the future of stem cell manufacturing - TechCentral.ie

Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells – BioSpace

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells.

The financial terms of the partnership include up to $760 million of development, regulatory, and sales milestones from Cytovia to Cellectis for the first 5 TALEN gene-edited iPSC-derived NK products (partnership products). Cellectis will also receive single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds.

We are excited to collaborate with Cellectis, a gene-editing pioneer and leader in the development of gene-edited allogeneic cancer therapies, to further accelerate Cytovias NK cell programs, said Dr. Daniel Teper, Chairman & CEO of Cytovia Therapeutics. Cellectis has a deep understanding and proven expertise in gene-edited cell therapies, and their gene editing technology, TALEN, will yield NK and CAR-NK treatments with improved potency, persistence, and safety for a variety of cancers, including solid tumors. We look forward to leveraging Cellectis insights and experience to help move Cytovias CAR-NKs into clinical trials by 2022.

Cellectis will develop custom TALEN, which Cytovia will use to edit iPSCs. Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis is granting Cytovia a worldwide license to its TALEN gene-editing technology, enabling Cytovia to modify NK cells addressing multiple gene targets for therapeutic use in several cancer indications.

We are thrilled to partner with Cytovia, a pioneer in the development of NK cells derived from iPSCs, said Dr. Andr Choulika, CEO of Cellectis. We are looking forward to this collaboration and the opportunity to further expand the potency of our proprietary TALEN gene-editing technology to iPSCs and CAR-NKs. Down the road, this collaboration should allow for NK cell therapies to be made available to cancer patients, which is very much in line with Cellectis mission to provide life-saving product candidates to address unmet patient needs in this field.

About Cellectis Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit http://www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN is a registered trademark owned by Cellectis.

About Cytovia Therapeutics Cytovia Therapeutics Inc. is a biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company is establishing R&D and GMP manufacturing operations in the greater Boston area and partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, INSERM, and CytoImmune Therapeutics. Learn more at http://www.cytoviatx.com and follow Cytovia Therapeutics on Social Media (Facebook, LinkedIn, Twitter, and Youtube).

About Gene-Edited, iPSC-derived NK Cells Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). In addition, CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent innovative developments with the induced pluripotent stem cell (iPSC)-derived CAR-NKs, an innovative technology, allow large quantities of true off-the-shelf, homogeneous genetically modified CAR NK cells to be produced from a gene-edited iPSC master cell bank, and thus hold promise to expand access to cell therapy for many patients.

For further information, please contact:

Cellectis Media contacts: Margaret Gandolfo, Communications Manager, 646-628-0300, margaret.gandolfo@cellectis.com Conor McGoldrick, Zeno Group, Assistant Account Executive, 914-355-0927, Conor.Mcgoldrick@zenogroup.com

Cellectis IR contact: Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Cytovia Investor Relations contact: Anna Baran-Djokovic VP of Investor Relations 646-355-1787 anna@cytoviatx.com

Cytovia Media contact: Chris Maggos LifeSci Advisors +41 79 367 6254 chris@lifesciadvisors.com

Disclaimer

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, believe, expected, forward looking, promising and will, or the negative of these and similar expressions. These forward-looking statements, are based on our managements current expectations and assumptions and on information currently available to management. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

PDF available at: http://ml.globenewswire.com/Resource/Download/c6bbee7d-f56e-400c-a6a4-28586a9e4851

Read more:
Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells - BioSpace

Induced Pluripotent Stem Cells Market Growth Opportunities, Analysis and Forecasts Report 2020-2026 with key players position (Fujifilm Holding…

The Induced Pluripotent Stem Cells Market grew in 2019, as compared to 2018, according to our report, Induced Pluripotent Stem Cells Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Induced Pluripotent Stem Cells Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025.

Deep analysis about Induced Pluripotent Stem Cells Market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Induced Pluripotent Stem Cells Market

Get a Sample Copy of the Report at: https://i2iresearch.com/download-sample/?id=8913

The Induced Pluripotent Stem Cells Market is analysed based on product types, major applications and key players

Key product type: Hepatocytes Fibroblasts Keratinocytes Amniotic Cells Others

Key applications: Academic Research Drug Development And Discovery Toxicity Screening Regenerative Medicine

Key players or companies covered are: Fujifilm Holding Corporation Astellas Pharma Fate Therapeutics Bristol-Myers Squibb Company ViaCyte Celgene Corporation Aastrom Biosciences Acelity Holdings StemCells Japan Tissue Engineering Organogenesis

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/need-customization/?id=8913

Key questions answered in the report: 1. What is the current size of the Induced Pluripotent Stem Cells Market, at a global, regional & country level? 2. How is the market segmented, who are the key end user segments? 3. What are the key drivers, challenges & trends that is likely to impact businesses in the Induced Pluripotent Stem Cells Market? 4. What is the likely market forecast & how will be Induced Pluripotent Stem Cells Market impacted? 5. What is the competitive landscape, who are the key players? 6. What are some of the recent M&A, PE / VC deals that have happened in the Induced Pluripotent Stem Cells Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us: i2iResearch info to intelligence Locational Office: *India, *United States, *Germany Email: [emailprotected] Toll-free: +1-800-419-8865 | Phone: +91 98801 53667Induced Pluripotent Stem Cells, Induced Pluripotent Stem Cells Market, Induced Pluripotent Stem Cells Market Size, Induced Pluripotent Stem Cells Market Growth, Induced Pluripotent Stem Cells Market forecast, Induced Pluripotent Stem Cells Industry, Induced Pluripotent Stem Cells Market Overview, Induced Pluripotent Stem Cells Market Share, Induced Pluripotent Stem Cells Trends, Induced Pluripotent Stem Cells Market Analysis, Induced Pluripotent Stem Cells Market Revenue, North America Induced Pluripotent Stem Cells Market, Europe Induced Pluripotent Stem Cells Market, Asia Pacific Induced Pluripotent Stem Cells Market, Middle East & Africa Induced Pluripotent Stem Cells Market

https://neighborwebsj.com/

Excerpt from:
Induced Pluripotent Stem Cells Market Growth Opportunities, Analysis and Forecasts Report 2020-2026 with key players position (Fujifilm Holding...